At MasKidney, Inc., we are at the forefront of developing innovative treatments to tackle Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD), a debilitating condition that leads to end-stage renal disease (ESRD) in all affected patients. Affecting over 50,000 individuals in the US, ADTKD is the third most common genetic disorder of the kidney
Founded in early 2024, we are pioneering a novel gene therapy to address the critical unmet need in ADTKD, a disease for which there are no treatments to delay or prevent progression end stage renal disease (ESRD). Our founders bring a wealth of experience and a strong commitment to advancing novel therapies in the field of kidney disease. We are driven by a shared mission to improve patient outcomes and have a positive impact in the realm of kidney health.